PRECISION GOLD Post Market Study in Europe of Pulmonary Vein Ablation Catheter (PVAC GOLD)

Inclusion Criteria: * Symptomatic AF (\>/=2 recurrent AF episodes that self terminate or AF \</=48 hours that are cardioverted) * Documentation of \>/=1 paroxysmal AF events within past year * AF symptoms (e.g. palpitations, fatigue, exertional dyspnea, effort intolerance) * Prescribed to vitamin K antagonist (e.g. warfarin/coumadin) * Age 18-70 years old * Clinically indicated for a pulmonary vein ablation * Willing and able to give informed consent * Willing, able and committed to participate in all study required activities for the duration of the study Exclusion Criteria: * Diagnosis of persistent or permanent AF * Prior left atrial ablation * Presence of intracardiac thrombus * Contraindicated for vitamin K antagonist * Prescribed to direct thrombin or factor inhibitors (e.g. dabigatran, rivaroxaban) * Prescribed to any investigational drug that may confound the study results * Cardiac valve prosthesis * Significant congenital heart defect (corrected or not) * Pulmonary vein stents * Pre-existing pulmonary vein stenosis * Cerebral ischemic event (e.g. stroke, TIA) that occurred within 6 months of study consent date * If female - pregnancy * Participation in any other cardiovascular clinical study * Contraindicated for MRI * Active sepsis * Blood clotting abnormalities (genetic) * Presence of left atrial myxoma * Venous filtering device (e.g. Greenfield filter) * Invasive cardiac procedure in past 90 days